Efficacy and safety of traditional Chinese medicine combined with routine western medicine for the asymptomatic novel coronavirus disease (COVID–19)

Abstract

Background: The number of patients infected with novel coronavirus disease (COVID–19) has exceeded 10 million in 2020, and a large proportion of them are asymptomatic. At present, there is still no effective treatment for this disease. Traditional Chinese medicine (TCM) shows a good therapeutic effect on COVID–19, especially for asymptomatic patients. According to the search results, we found that although there are many studies on COVID–19, there are no studies targeting asymptomatic infections. Therefore, we design a network meta-analysis (NMA) to evaluate the therapeutic effect of TCM on asymptomatic COVID–19. Methods: We will search Chinese and English databases to collect all randomized controlled trials (RCTs) of TCM combined with conventional western medicine or using only TCM to treat asymptomatic COVID–19 from December 2019 to July 2020. Then, two investigators will independently filter the articles, extract data, and evaluate the risk of bias. We will conduct a Bayesian NMA to evaluate the effects of different therapies. All data will be processed by Stata 16.0 and WinBUGS. Results: This study will evaluate the effectiveness of various treatments for asymptomatic COVID–19. The outcome indicators include the time when the nucleic acid turned negative, the proportion of patients with disease progression, changes in laboratory indicators, and the side effects of drugs. Conclusion: This analysis will further improve the treatment of asymptomatic COVID–19. INPLASY registration number: INPLASY202070022.

Efficacy and safety of integrated traditional Chinese and Western medicine against COVID‐19: A systematic review and meta‐analysis

“…A total of 53 peer‐reviewed articles (Ai Xy, Lp, et al, 2020; Chen Cw, Yf, et al, 2021; Chen Ling, Wu, et al, 2020; Chen Lz & Gl, 2020; Cheng Dz, Li, et al, 2020; Dai Gc, Ww, et al, 2020; Ding Xj, Dc, et al, 2020; Duan, Cj, et al, 2020; Fu Xx & Tan, 2020; He Qing, Xw, et al, 2021; He & Z., 2021; Hu et al, 2021; Ji & P, 2020; Jin, L, Zhao, et al, 2020; Li, A, Jk, et al, 2021; Li Qj, Wang, et al, 2021; Lian, S, Gl, et al, 2020; Liu, 2020; Liu, 2021; Liu Ap, Jw, et al, 2021; Liu Kf, Zp, et al, 2020; Luo, K, Yl, et al, 2022; Lv Rb & Li, 2020; Qian Yj, Wang, et al 2020; Qin Yl, Zhou, et al, 2020; Qiu, Q, Dp, et al, 2020; Qu Xk, Ma Jing, et al, 2020; Shi Sf, Xiong, et al, 2021; Shi, Z, Ye, et al, 2020; Song Yy, Zhou, et al, 2020; Su Qw, Tao, et al, 2020; Sun Hm, Zhang, et al, 2020; Wang, C, Zheng, et al, 2021; Wang, G, Xy, et al, 2021; Wang Xl, Zhao, et al, 2020; Wang Yj, Yan, et al, 2020; Xia Wg, Cj, et al, 2020; Xiao, J, Ss, et al, 2020; Xiao Mz, 2020; Xiao, X, Wk, et al, 2021; Xin Sy et al, 2020; Xu, D, Sh, et al, 2020; Yang Mf, Huang, et al, 2020; Yao Kt, Li, et al, 2020; Yu, L, Sb, et al, 2020; Yu Xy, Ff, et al, 2020; Zeng, M, & Wang, 2020; Zhang Cy, Zhang, et al, 2020; Zhang Jy, Xj, et al, 2021; Zhang Xy et al, 2021; Zhang Yl, Xu, et al, 2020; Zhou et al, 2021) were included for qualitative and quantitative analysis, including 20 retrospective cohort study(RCS) and 33 RCTs, 41 single center studies and 12 multi‐center studies. Of the 5425 inclu...…”

Comparative efficacy of eight therapeutic methods in the treatment of left main coronary artery disease: a Bayesian network meta-analysis protocol

“…In previous Meta-analysis publication,22 we used ADDIS software, it will be different next. We plan to use STATA V.16.0 software to draw a network diagram of the comparison of various interventions, and use Markov Chain Monte Carlo method to simulate, the number of iterations is set to 50,000 23. Interstudy heterogeneity will be evaluated by the Q statistic, where p<0.10 will be considered statistically significant and informative by I 2 statistic, where I 2 ≥50% will indicate heterogeneity.…”

Traditional herbs against COVID-19: back to old weapons to combat the new pandemic

“…Besides, SARS-CoV-2 has a furin-like cleavage site at the S1–S2 junction, lacking in other allies of its sister clade. The superior pathogenicity of SARS-CoV-2 could be attributed to this additional cleavage site, since it similarly occurs in the extremely contagious forms of influenza virus, however, missing in less infectious ones [ 17 ].…”

“…In addition, SARS-CoV-2 was detected in the fecal sample, even urine and saliva of corona-ill patients. Therefore, fecal–oral transmission could also be a possible route of viral transmission [ 17 ].…”